The company is on track to produce 1 billion doses for global distribution by the end of 2021, which would generate up to $10 billion. In August, Johnson & Johnson reached a more than $1 billion agreement with the United States for 100 million doses of its vaccine, with the option to purchase an additional 200 million doses, for $10 per shot. In addition, Johnson & Johnson reached an agreement with the E.U. for up to 400 million doses.
CDC and FDA have recommended a pause in the use of the Johnson & Johnson’s Janssen COVID-19 vaccine in the United States out of an abundance of caution, effective Tuesday, April 13. CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, to address this issue. People who have received the J&J/Janssen COVID-19 vaccine within the past three weeks who develop severe headache, abdominal pain, leg pain, or shortness of breath should contact their health care provider.
